Next Article in Journal / Special Issue
Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication
Previous Article in Journal
Cell Type-Selective Expression of Circular RNAs in Human Pancreatic Islets
Article Menu

Export Article

Open AccessCommunication
Non-Coding RNA 2018, 4(4), 39; https://doi.org/10.3390/ncrna4040039

Upregulation of Long Non-Coding RNA DRAIC Correlates with Adverse Features of Breast Cancer

1,†,* and 1,2
1
Department of Genetics and Cell Biology, College of Life Sciences, Nankai University, Tianjin 300071, China
2
Department of Hematology and Medical Oncology, School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Current address: Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
*
Author to whom correspondence should be addressed.
Received: 3 November 2018 / Revised: 30 November 2018 / Accepted: 7 December 2018 / Published: 11 December 2018
(This article belongs to the Special Issue Non-Coding RNA in Reproductive Organ Cancers)
Full-Text   |   PDF [2251 KB, uploaded 11 December 2018]   |  

Abstract

DRAIC (also known as LOC145837 and RP11-279F6.1), is a long non-coding RNA associated with several types of cancer including prostate cancer, lung cancer, and breast cancer. Its expression is elevated in tumor tissues compared to adjacent benign tissues in breast cancer patients and is regulated by estrogen treatment in breast cancer cells. In addition, expression analysis of DRAIC in more than 100 cell lines showed that DRAIC expression is high in luminal and basal subtypes compared to claudin low subtype, suggesting a prognostic value of DRAIC expression in breast cancer. In the present study, we analyzed DRAIC expression in 828 invasive breast carcinomas and 105 normal samples of RNA sequencing datasets from The Cancer Genome Atlas (TCGA) and found that DRAIC expression was correlated with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, and is increased in cancerous tissues. Additionally, higher DRAIC expression was associated with poorer survival of patients, especially in ER positive breast cancer. DRAIC was also investigated in the Oncomine database and we found that DRAIC expression predicted patients’ response to paclitaxel and FEC as well as lapatinib, which are commonly used therapy options for breast cancer. Finally, DRAIC expression in breast cancer was negatively correlated with immune cell infiltration. These results reinforce the importance of DRAIC in breast cancer. View Full-Text
Keywords: lncRNA; DRAIC; LOC145837; RP11-279F6.1; breast cancer lncRNA; DRAIC; LOC145837; RP11-279F6.1; breast cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Zhao, D.; Dong, J.-T. Upregulation of Long Non-Coding RNA DRAIC Correlates with Adverse Features of Breast Cancer. Non-Coding RNA 2018, 4, 39.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Non-Coding RNA EISSN 2311-553X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top